Dr. Diana Escolar is back and her trial ACE-031 will be underway soon - and there will be five sites in the US for the next trial.  FDA loves the trial.  Cannot wait for it.  It may beat Prosensa (GSK) trial here.   Yesterday, she began seeing patients again, only four per month so she can devote the rest of her time to research.  SHe is completely excited about this trial.